SymBio Pharmaceuticals: Settlement of Patent Infringement Lawsuit Relating to “Treaxine”
SymBio Pharmaceuticals: An international Phase Ib clinical trial targeting malignant lymphoma patients using injectable Brincidofovir as a First in Human (FIH) study in the field of cancer has started.
SymBio Pharmaceuticals: Confirmatory letter.
SymBio Pharmaceuticals: Semiannual Report - 20th Period (01/01/2024 - 12/31/2024)
SymBio Pharmaceuticals: Short message of the consolidated financial statements for the second quarter of the fiscal year ending December 2024 [Japan Standards]
SymBio Pharmaceuticals: Summary of Consolidated Financial Statements for the First Six Months of the Fiscal Year Ending on December 31, 2024 [Japan GAAP]
SymBio Pharmaceuticals: Change report.
SymBio Pharmaceuticals: Pennsylvania State University's School of Medicine has announced research findings that the antiviral drug brincidofovir suppresses the production of infectious viruses in the polyomavirus.
SymBio Pharmaceuticals: Confirmed antitumor effect of brentuximab vedotin on peripheral T-cell lymphoma (PTCL), inducing suppression of oncogene MYC and expression of immune regulatory genes.
SymBio Pharmaceuticals: FPI (the first case) was achieved in the phase 2a clinical trial of the injection brincidofovir targeting patients with cytomegalovirus infection after hematopoietic stem cell transplantation.
SymBio Pharmaceuticals: Notice Concerning Appointment of Executive Officers
SymBio Pharmaceuticals: Notice of commencement of clinical trials targeting cytomegalovirus infection after hematopoietic stem cell transplantation in a phase 2a clinical trial (ATHENA trial) with the injectable brincidofovir
SymBio Pharmaceuticals: Quarterly Report - 20th Quarter 1 (2024/01/01 - 2024/03/31)
SymBio Pharmaceuticals: Confirmation letter
SymBio Pharmaceuticals: Revision of the 2024 earnings forecast
SymBio Pharmaceuticals: Notice regarding revisions to the full-year earnings forecast for the fiscal year ending 2024/12
SymBio Pharmaceuticals: Summary of consolidated financial statements for the first three months of the fiscal year ending December 31, 2024 [Japanese Standards]
SymBio Pharmaceuticals: Summary of Financial Results for the 1st Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
SymBio Pharmaceuticals: Notice regarding confirmation of the details of the issuance of stock acquisition rights (stock options) to be issued to our employees
SymBio Pharmaceuticals: Notice regarding determination of the details of the issuance of stock acquisition rights (stock options) to be issued to our directors
No Data
No Data